1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation
- Resource Type
- Abstract
- Source
- In
Annals of Oncology September 2020 31 Supplement 4:S710-S711 - Subject
- Language
- ISSN
- 0923-7534